Journal article
The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium
F Guida, VY Tan, LJ Corbin, K Smith-Byrne, K Alcala, C Langenberg, ID Stewart, AS Butterworth, P Surendran, D Achaintre, J Adamski, PA Exezarreta, MM Bergmann, CJ Bull, CC Dahm, A Gicquiau, GG Giles, MJ Gunter, T Haller, A Langhammer Show all
Plos Medicine | Published : 2021
Abstract
Background Excess bodyweight and related metabolic perturbations have : been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI). Methods and findings We assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case-control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25..
View full abstractRelated Projects (1)
Grants
Awarded by Economic and Social Research Council
Funding Acknowledgements
The metabolomics analysis of this study was supported by World Cancer Research Fund (reference: 2014/1193, MJ) and the European Commission (FP7: BBMRI-LPC; reference: 313010, MJ). The work was supported by a Cancer Research UK Programme Grant [The Integrative Cancer Epidemiology Programme, ICEP] (C18281/A19169, NJT). This research was funded in whole, or in part, by the Wellcome Trust (20280Y2/Z/16/Z, NJT). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC, MJ) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC, ER). The national cohorts are supported by: Danish Cancer Society (Denmark, CCD); Ligue Contre le Cancer (GS), Institut Gustave Roussy (GS), Mutuelle Ge ' ne ' rale de l'Education Nationale (GS), Institut National de la Sante ' et de la Recherche Me ' dicale (INSERM) (France, GS); German Cancer Aid, German Cancer Research Center (DKFZ, MMB), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE, MMB), Federal Ministry of Education and Research (BMBF) (Germany, MMB); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy,Epidemiology, Institute of Epidemiology, Helmholtz Zentrum Munchen, German Research Center for Environmental Health (GmbH), Neuherberg, Germany